$110,000.00 in Sales Expected for Celsion Co. (NASDAQ:CLSN) This Quarter

Equities research analysts expect that Celsion Co. (NASDAQ:CLSNGet Rating) will announce sales of $110,000.00 for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Celsion’s earnings. The lowest sales estimate is $100,000.00 and the highest is $130,000.00. Celsion posted sales of $130,000.00 in the same quarter last year, which would indicate a negative year-over-year growth rate of 15.4%. The company is scheduled to issue its next earnings report on Monday, January 1st.

On average, analysts expect that Celsion will report full-year sales of $500,000.00 for the current year. For the next financial year, analysts expect that the firm will report sales of $500,000.00. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Celsion.

A number of equities research analysts recently weighed in on CLSN shares. StockNews.com assumed coverage on Celsion in a research report on Wednesday. They set a “hold” rating on the stock. HC Wainwright assumed coverage on Celsion in a report on Wednesday, April 13th. They issued a “buy” rating and a $16.00 target price on the stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Morgan Stanley increased its stake in shares of Celsion by 44.6% during the third quarter. Morgan Stanley now owns 2,332,078 shares of the biotechnology company’s stock valued at $2,156,000 after buying an additional 719,758 shares during the period. Geode Capital Management LLC increased its stake in Celsion by 7.8% during the 3rd quarter. Geode Capital Management LLC now owns 756,885 shares of the biotechnology company’s stock valued at $699,000 after purchasing an additional 54,785 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Celsion in the 2nd quarter worth $228,000. GSA Capital Partners LLP boosted its holdings in shares of Celsion by 435.2% during the 4th quarter. GSA Capital Partners LLP now owns 133,006 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 108,155 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Celsion during the 4th quarter valued at $59,000. Institutional investors and hedge funds own 10.75% of the company’s stock.

Shares of CLSN stock opened at $2.94 on Friday. The company has a current ratio of 7.67, a quick ratio of 7.67 and a debt-to-equity ratio of 0.10. Celsion has a 1 year low of $2.81 and a 1 year high of $23.25. The stock has a market cap of $16.97 million, a P/E ratio of -0.75 and a beta of 2.11. The stock has a 50 day simple moving average of $4.62 and a 200 day simple moving average of $8.03.

About Celsion (Get Rating)

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.

See Also

Get a free copy of the Zacks research report on Celsion (CLSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celsion (NASDAQ:CLSN)

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.